The present invention is directed to a combination of an RSV inhibiting compound A, i.e. 3 - ({5-chloro-1- [3- (methylsulfonyl) propyl] -1H-indole-2-yl} methyl) -1- (2,2,2-trifluoroethyl) -1,3-dihydro-2H- imidazo [4,5-c] pyridin-2-one, and one or more RSV inhibiting compounds B selected from ribavirin, GS-5806, MDT-637, BTA-9881, BMS-433771, YM-543403, A-60444 , TMC-353121, RFI-641, CL-387626, MBX-300, AZ-27, MEDI8897, CR9501, palivizumab, 3 - ({5-chloro-1- [3- (methylsulfonyl) propyl] -1H-benzimidazole 2-yl} methyl) -1-cyclopropyl-1,3-dihydro-2H-imidazo [4,5-c] pyridin-2-one, 3 - [[7-chloro-3- (2-ethylsulfonylethyl) imidazo [ 1,2-a] pyridin-2-yl] methyl] -1-cyclopropylimidazo [4,5-c] pyridin-2-one, N- (2-fluoro-6-methylphenyl) -6- (4- (5 -methyl-2- (7-oxa-2-azaspiro [3.5] nonan-2-yl) nicot Namido) benzoyl) -5,6-dihydro-4H-benzo [b] thieno [2,3-d] azepine-2-carboxamide and 4-amino-8- [3 - [[2- (3,4-dimethoxyphenyl ) ethyl] amino] propyl] -6,6-dimethyl-2- (4-methyl-3-nitrophenyl) -3H-imidazo [4,5-h] isoquinoline-7,9 (6H, 8H) -dione, intended for treating or reducing the intensity of RSV infection. The present invention further relates to a combination product based on compound A and one or more compounds B, to a pharmaceutical product containing compound A and one or more compounds B, to the use of a combination of compound A and one or more compounds B or a pharmaceutical product containing compound A and one or more compounds B for the treatment of RSV infection and to a method for treating or reducing the intensity of RSV infection in a subject in need thereof administering a combination of compound A and one or more compounds B in an effective amount to a specified subject.Настоящее изобретение направлено на комбинацию ингибирующего RSV соединения A, т.е. 3-({5-хлор-1-[3-(метилсульфонил)пропил]-1H-индол-2-ил}метил)-1-(2,2,2-трифторэтил)-1,3-дигидро-2H-имидазо[4,5-c]пиридин-2-она, и одного или нескольких ингибирующих RSV соединений B, выбранных из рибавирина, GS-5
